The Brief

Monsanto, Glyphosate, and the Manipulation of the Scientific Record

United States, 2000–2025

This Brief is an AI-generated synthesis of the public record. It may contain errors, omissions, or out-of-date information, and is not legal advice or original reporting. Verify against the primary sources before relying on it.

SECTION 1 — VERDICT

The documented record establishes that Monsanto manipulated the scientific literature on glyphosate to a degree that is rare in its scale, its deliberateness, and its regulatory consequences. Internal company documents disclosed in US litigation — the Monsanto Papers — show that Monsanto employees, led by toxicologist Dr. William F. Heydens, ghostwrote a 2000 safety review published in Regulatory Toxicology and Pharmacology under the names of three academic scientists; that Heydens and colleagues recruited those academics specifically to lend independent credibility to a company-directed text; that Monsanto subsequently cited that ghostwritten study in regulatory submissions to the EPA and other agencies as if it were independent peer-reviewed science; and that the company mounted a coordinated campaign to discredit the IARC's 2015 "probably carcinogenic" finding before it was even published. The 2025 retraction of the 2000 study by the journal — citing undisclosed Monsanto authorship and reliance on company data — is the formal academic ratification of what the Monsanto Papers had already shown. On the narrower question of whether Monsanto corruptly influenced the EPA's review process, the evidence is more circumscribed but significant: internal Monsanto emails document that in April 2015, Monsanto regulatory affairs manager Dan Jenkins recounted a conversation in which senior EPA official Jess Rowland — then chair of the EPA's Cancer Assessment Review Committee — said regarding a planned ATSDR glyphosate review that "if I can kill this I should get a medal." Internal Monsanto documents express confidence that Rowland would manage the EPA's own assessment favorably. The EPA's consistent finding that glyphosate is not likely carcinogenic — diverging sharply from IARC — was reached through a committee chaired by an official who, by his own documented words recounted by the regulated company, was operating as an ally of that company. Whether Rowland's actions altered the EPA's substantive conclusion cannot be proven from available evidence; that the company believed he could and would do so is documented in its own words.

The strong circumstantial reading — the institutional reading that the evidence elevates — is that Monsanto Corporation manipulated the scientific and regulatory record on glyphosate's carcinogenicity as a deliberate strategy to protect its flagship product from adverse findings, and that this manipulation shaped the regulatory environment in which Roundup remained on the market for decades. The company had power: the financial and institutional capacity to fund safety studies, retain regulators as allies, and litigate for decades. It had motive: Roundup was a multi-billion-dollar product line central to Monsanto's genetically-modified seed strategy. The history pillar requires closer examination. Direct precedent for academic ghostwriting — the specific mechanism at the center of this case — is not independently established in Monsanto's prior conduct; the Brief cannot claim that Monsanto had previously ghostwritten safety studies in the same manner. However, the methodology directs attention to adjacent operational history: conduct in different domains that reveals the same institutional reflexes. Monsanto's history on this wider view is substantial and documented. The company manufactured polychlorinated biphenyls (PCBs) for decades while internal documents — disclosed in litigation that produced a $700 million settlement with the State of Washington and other substantial judgments — showed corporate knowledge of PCB toxicity dating to the 1950s and a deliberate strategy of concealing that knowledge from regulators and the public. The company was a primary manufacturer of Agent Orange for use in Vietnam and denied dioxin contamination for years despite internal awareness. Neither case involved ghostwriting academic literature; both cases involved the same operational signature at the institutional level: a corporation aware of a product's toxicity, deploying legal, scientific, and regulatory strategies to prevent that knowledge from producing regulatory or liability consequences. This is adjacent history under the methodology — not the same specific act, but the same institutional operational style applied across different products and different decades. The supplementary indicators further strengthen the case: the operational signature of the ghostwriting itself (Heydens' emails discussing the recruitment strategy are a contemporaneous institutional fingerprint); the suppression pattern (coordinated pre-publication discrediting of IARC, rapid cultivation of regulatory allies, the documented offer by the CARC chair to kill an interagency review); and the structural beneficiary (Monsanto's entire GMO product architecture depended on glyphosate's safety profile). Three juries in two court systems found Roundup caused plaintiffs' cancer and Monsanto failed to warn. Bayer committed over ten billion dollars to settle claims within two years of acquiring Monsanto. The 2025 retraction formally closed the loop on the ghostwritten study. No single piece of evidence is a smoking gun; together they form a pattern of conduct that an honest investigator cannot dismiss as coincidence or isolated bad judgment. This reading cannot be proven from available public evidence in the narrow sense that no document records a corporate officer stating "we know this product causes cancer and we are concealing it." It also cannot be dismissed.

What the evidence cannot establish is whether glyphosate itself, at real-world exposure levels, causes non-Hodgkin lymphoma in humans. The IARC classification addresses hazard (can this substance cause cancer under some circumstances?) and placed glyphosate in Group 2A — "probably carcinogenic" — on the basis of limited human evidence and sufficient animal evidence. The EPA, the European Food Safety Authority, and other regulatory bodies have assessed risk (does this substance cause cancer at actual exposure levels?) and concluded it does not. The jury verdicts in Johnson, Hardeman, and Pilliod were reached under the civil standard of preponderance of evidence, and each was substantially reduced on appeal. The question of causation at the epidemiological level remains genuinely contested among qualified scientists, with the large prospective Agricultural Health Study finding no statistically significant association between glyphosate exposure and NHL, while several case-control studies and meta-analyses do find associations. What the Monsanto Papers establish is not the answer to that scientific question. What they establish is that Monsanto worked systematically to ensure that the question would never get a clean answer from independent science operating without corporate influence.

SECTION 2 — CASE SUMMARY

Glyphosate is a broad-spectrum herbicide developed by Monsanto and brought to market in 1974 under the trade name Roundup. It became the most widely used herbicide in the world, and its importance to Monsanto multiplied after 1996 when the company introduced "Roundup Ready" genetically modified crops — soybeans, corn, cotton — engineered to tolerate glyphosate, allowing farmers to spray the herbicide freely without killing the crop. The herbicide and the seeds became an integrated product system generating billions of dollars annually, and glyphosate's safety profile was foundational to the entire enterprise. In March 2015, the International Agency for Research on Cancer, a specialized agency of the World Health Organization, published Monograph 112, which classified glyphosate as Group 2A — "probably carcinogenic to humans." The IARC working group, composed of seventeen scientists from eleven countries, reviewed publicly available studies and found "limited" evidence of carcinogenicity in humans and "sufficient" evidence in experimental animals. The finding was not a regulatory action — IARC identifies hazards, not risks — but it had immediate regulatory and commercial implications, triggering re-evaluations worldwide and providing the scientific anchor for the first wave of litigation by agricultural workers and home gardeners who had developed non-Hodgkin lymphoma after using Roundup.

Monsanto's response was swift and aggressive: the company denounced the IARC finding as flawed science, demanded retraction of the monograph, and worked to persuade regulatory agencies — particularly the EPA — to reject IARC's conclusions. What transformed public understanding of the case was the disclosure, through discovery in US civil litigation beginning in 2017, of internal Monsanto documents — tens of thousands of pages of emails, memoranda, and strategy documents that became known as the Monsanto Papers. These documents revealed that Monsanto toxicologist Dr. William F. Heydens had ghostwritten a 2000 safety review of glyphosate published under the names of three independent academic scientists (Dr. Gary M. Williams of New York Medical College, Dr. Robert Kroes of Utrecht University, and Dr. Ian C. Munro of Cantox Health Sciences International); that Heydens had explicitly discussed the strategy of recruiting academic scientists to serve as "external authors" for company-drafted text to confer independent credibility on Monsanto's conclusions; and that Monsanto had used the resulting publication in regulatory submissions for more than a decade as if it were independent peer-reviewed science. The documents also revealed communications between Monsanto and Jess Rowland, then chair of the EPA's Cancer Assessment Review Committee, in which Rowland indicated he could "kill" a planned review of glyphosate by the Agency for Toxic Substances and Disease Registry — Monsanto regulatory affairs manager Dan Jenkins recounted in an internal email that Rowland had said "if I can kill this I should get a medal" — and internal Monsanto documents expressed confidence that Rowland would manage the EPA's own assessment favorably.

The litigation arc intensified dramatically. In June 2018, Bayer AG — a German pharmaceutical and chemical conglomerate — acquired Monsanto for $63 billion. Two months later, in August 2018, a California state-court jury in San Francisco Superior Court before Judge Suzanne Bolanos returned a $289 million verdict in Johnson v. Monsanto, finding that Roundup caused plaintiff Dewayne Johnson's non-Hodgkin lymphoma and that Monsanto had failed to warn of the risk. The verdict was later reduced to $78 million. Bayer shareholders, not legacy Monsanto shareholders, now bore the financial exposure. In 2019, a federal MDL bellwether jury in San Francisco before Judge Vince Chhabria found for plaintiff Edwin Hardeman ($80 million, reduced to $25 million), and an Alameda County Superior Court jury before Judge Winifred Smith found for plaintiffs Alva and Alberta Pilliod (over $2 billion, reduced to $87 million). Monsanto had now lost in two different court systems — California state and federal — before three different juries. In June 2020, Bayer announced it would pay approximately $10–11 billion to settle roughly 125,000 filed and unfiled Roundup claims, while maintaining that glyphosate is safe. In November 2025, the journal Regulatory Toxicology and Pharmacology formally retracted the ghostwritten 2000 study, citing undisclosed Monsanto authorship and reliance on company data — an institutional acknowledgment arriving eight years after the Monsanto Papers had first exposed the ghostwriting.

SECTION 3 — FULL RECORD

Evidentiary Posture

The evidence base for this case is unusually rich for a corporate-conduct investigation. The central evidentiary resource is the Monsanto Papers: internal company documents disclosed through civil discovery in US litigation (principally the Roundup multidistrict litigation in the Northern District of California, MDL No. 2741, presided over by Judge Vince Chhabria, and parallel state-court proceedings). These documents are primary-source material — emails between named Monsanto employees (including toxicologist Dr. William F. Heydens and regulatory affairs manager Dan Jenkins), strategy memoranda, draft manuscripts with tracked changes showing Monsanto authorship, and communications with regulators. Their authenticity has been established through the discovery process and they have been admitted as evidence in multiple trials. They are contemporaneous records of what Monsanto employees were doing and saying internally, carrying the weight of documents created in the ordinary course of business.

Alongside the Monsanto Papers, the record includes: the IARC Monograph 112 (2015), a formal institutional finding by a WHO agency produced through a documented process with a declared working group; EPA regulatory determinations through 2020, reached by a process whose independence is contested due to the Rowland communications; jury verdicts in Johnson (California Superior Court), Hardeman (federal MDL), and Pilliod (California Superior Court), each substantially reduced on appeal; the reported 2025 retraction of the 2000 study (see provenance note above); and a contested epidemiological literature including the Agricultural Health Study and multiple meta-analyses.

What is absent: no direct internal Monsanto document states that glyphosate causes cancer. No suppressed study has emerged showing a definitive causal link that the company concealed. The concealment the documents reveal is of the company's role in shaping the scientific literature — not of a specific carcinogenicity finding that the company knew about and hid.

Observed Facts vs. Inferred Claims

Observed facts (established by primary or multiply-corroborated sources):

Monsanto toxicologist Dr. William F. Heydens and colleagues drafted substantial portions of the 2000 Williams-Kroes-Munro safety review, which was published under the names of three academic scientists — Dr. Gary M. Williams (New York Medical College), Dr. Robert Kroes (Utrecht University), and Dr. Ian C. Munro (Cantox Health Sciences International) — without disclosure of Monsanto's authorship role. (Source: Monsanto Papers internal emails from Heydens and draft manuscripts with tracked changes.)
Heydens' internal Monsanto emails discussed recruiting academic scientists to serve as "external authors" for company-produced text, with the explicit goal of securing independent credibility for the publication. (Source: Monsanto Papers; Heydens emails.)
The 2000 study was cited by Monsanto in regulatory submissions to the EPA and other agencies for years following its publication. (Source: regulatory dockets and Monsanto submissions.)
Monsanto developed a coordinated strategy to respond to the anticipated IARC finding before it was published, including plans to engage third-party scientists to publish rebuttals without disclosing Monsanto's role. (Source: internal Monsanto strategy documents and emails.)
In April 2015, Monsanto regulatory affairs manager Dan Jenkins sent an internal email recounting a conversation with Jess Rowland, then chair of the EPA's Cancer Assessment Review Committee, in which Rowland said regarding a planned ATSDR glyphosate review: "if I can kill this I should get a medal." (Source: Monsanto Papers; Jenkins email.)
Internal Monsanto documents express confidence that Rowland would manage the EPA's glyphosate assessment favorably to Monsanto. (Source: Monsanto Papers.)
The IARC, in March 2015, classified glyphosate as Group 2A — "probably carcinogenic to humans." (Source: IARC Monograph 112.)
The EPA, through its Cancer Assessment Review Committee chaired by Rowland, maintained that glyphosate is not likely to be carcinogenic to humans. (Source: EPA regulatory determinations, through 2020.)
Three juries in two different court systems — California state court (Johnson, Pilliod) and federal MDL (Hardeman) — found that Roundup caused the plaintiffs' non-Hodgkin lymphoma and that Monsanto failed to warn. (Source: court records.)
The damage awards in all three cases were substantially reduced on appeal. In Johnson, Judge Suzanne Bolanos reduced the $289 million verdict to $78 million; in Hardeman, Judge Vince Chhabria reduced $80 million to $25 million; in Pilliod, Judge Winifred Smith reduced over $2 billion to $87 million. (Source: post-trial rulings.)
Bayer AG acquired Monsanto in June 2018 for $63 billion. The Johnson verdict — the first trial loss — was delivered in August 2018, two months after the acquisition closed. (Source: Bayer corporate announcements; court records.)
Bayer AG committed approximately $10–11 billion in June 2020 to settle roughly 125,000 Roundup claims. (Source: Bayer corporate announcements and SEC filings.)
In November 2025, the journal Regulatory Toxicology and Pharmacology formally retracted the 2000 Williams-Kroes-Munro study, citing undisclosed Monsanto authorship and reliance on company data. The fact of ghostwriting is independently established through the Monsanto Papers; the retraction ratifies it institutionally.

Inferred claims (supported but not directly observed):

That Monsanto's ghostwriting and scientist-recruitment strategy was part of a deliberate, multi-year effort to create a body of scientific literature supporting favorable regulatory determinations, rather than an ad hoc or isolated incident. Strength of inference: strong. Heydens' emails show planning and strategic intent; the study was then deployed in regulatory submissions for more than a decade.
That Rowland's intervention influenced the EPA's glyphosate assessment. Strength of inference: moderate. The documents show Rowland's willingness to act as an ally and Monsanto's confidence that he would deliver; they do not provide a direct causal chain from Rowland's specific actions to the EPA's specific conclusions.
That the IARC-EPA divergence reflects, at least in part, Monsanto's success in shaping the evidence environment on which the EPA relied. Strength of inference: moderate. The EPA's assessment relied on a different body of evidence than IARC's, including unpublished industry studies and a published literature contaminated by the ghostwritten study.

Figure Inventory

Figure	Role	Confidence
Monsanto Company (acquired by Bayer AG, June 2018)	Manufacturer of Roundup; central institutional actor	DOCUMENTED
Bayer AG	German chemical and pharmaceutical company; acquired Monsanto for $63 billion in June 2018; assumed liability for Roundup claims; committed ~$10–11 billion to settle ~125,000 claims in June 2020	DOCUMENTED
Dr. William F. Heydens	Monsanto toxicologist; internal emails document his role in ghostwriting the 2000 study and discussing the recruitment of academic "external authors" to confer independent credibility on company-prepared text	DOCUMENTED — role established through Monsanto Papers emails and draft manuscripts with tracked changes; living
Dan Jenkins	Monsanto regulatory affairs manager; authored the April 2015 internal email recounting Jess Rowland's statement that "if I can kill this I should get a medal" regarding the ATSDR review	DOCUMENTED — role established through Monsanto Papers; living
Jess Rowland	Senior EPA official; chair of the EPA's Cancer Assessment Review Committee; documented in Monsanto emails as offering to "kill" the ATSDR glyphosate review and as an ally inside the EPA	DOCUMENTED — role and communications established through Monsanto Papers; living
Dr. Gary M. Williams	Professor, New York Medical College; named academic author on the 2000 ghostwritten study; recruited by Monsanto as an "external author" for company-prepared text	DOCUMENTED — role as named author established; recruitment documented in Heydens' internal emails; living status not confirmed
Dr. Robert Kroes	Professor, Utrecht University; named academic author on the 2000 ghostwritten study	DOCUMENTED — as above; living status not confirmed
Dr. Ian C. Munro	Cantox Health Sciences International; named academic author on the 2000 ghostwritten study	DOCUMENTED — as above; living status not confirmed
IARC (International Agency for Research on Cancer)	WHO specialized agency; published Monograph 112 classifying glyphosate as Group 2A "probably carcinogenic" in March 2015	DOCUMENTED — institutional actor
US EPA (Environmental Protection Agency)	Federal regulatory agency; through its Cancer Assessment Review Committee, maintained glyphosate is not likely carcinogenic	DOCUMENTED — institutional actor
ATSDR (Agency for Toxic Substances and Disease Registry)	CDC agency; had planned a glyphosate review that Rowland allegedly worked to block	DOCUMENTED — institutional actor
Dewayne Johnson	First Roundup plaintiff to reach trial; school groundskeeper who developed NHL after using Roundup; California state court jury awarded $289M (reduced to $78M by Judge Bolanos)	DOCUMENTED
Edwin Hardeman	First federal MDL bellwether plaintiff; used Roundup for decades on his property; jury awarded $80M (reduced to $25M by Judge Chhabria)	DOCUMENTED
Alva and Alberta Pilliod	California state-court plaintiffs; couple who used Roundup for residential landscaping and both developed NHL; jury awarded over $2B (reduced to $87M by Judge Smith)	DOCUMENTED
Judge Vince Chhabria	US District Judge, Northern District of California; presided over federal Roundup MDL (MDL No. 2741); made key evidentiary rulings; reduced Hardeman damages	DOCUMENTED
Judge Suzanne Bolanos	San Francisco County Superior Court judge; presided over Johnson v. Monsanto state-court trial; reduced $289M verdict to $78M	DOCUMENTED
Judge Winifred Smith	Alameda County Superior Court judge; presided over Pilliod v. Monsanto state-court trial; reduced over $2B verdict to $87M	DOCUMENTED
Dr. Christopher Portier	Scientist who contributed to IARC review; later publicly defended the IARC classification against EPA criticism	DOCUMENTED
Dr. Aaron Blair	Epidemiologist; chaired the IARC Working Group for Monograph 112	DOCUMENTED
EFSA (European Food Safety Authority)	EU regulatory body; concluded glyphosate is unlikely to pose a carcinogenic hazard to humans	DOCUMENTED — institutional actor
Regulatory Toxicology and Pharmacology	Academic journal published by Elsevier; published the 2000 ghostwritten study and retracted it in November 2025	DOCUMENTED — institutional actor

Named Living Individuals Associated with the Institutional Candidate

The methodology requires that named living individuals associated with the candidate organized power be addressed in a dedicated sub-section as reportage of documented allegations. The institutional candidate — Monsanto Corporation — carries the elevated reading. The individuals below are addressed as parties to the documented public record, not as the subjects of the Brief's own elevated reading. Each entry reports what the documented record establishes, what allegations have been made and by whom, and what the evidence does and does not support.

Jess Rowland — EPA Cancer Assessment Review Committee Chair. The Monsanto Papers establish that Rowland, while chairing the EPA committee responsible for the agency's glyphosate cancer assessment, communicated with Monsanto regulatory affairs manager Dan Jenkins. Jenkins' internal email of April 2015 recounts Rowland stating, regarding a planned ATSDR glyphosate review, "if I can kill this I should get a medal." Internal Monsanto documents express confidence that Rowland would manage the EPA's assessment favorably. What the evidence establishes: Rowland, a senior EPA official, communicated with a regulated company in terms that indicated he was acting as an ally of that company against an interagency review. What has been alleged: plaintiffs' counsel and critics of the EPA's glyphosate assessment have argued that Rowland's relationship with Monsanto corrupted the agency's cancer review. What the evidence does not establish: no evidence has emerged of payments or a direct quid pro quo between Monsanto and Rowland. The specific actions Rowland took within the EPA, the internal deliberations he participated in, and the precise influence he exerted on the CARC's conclusions are not documented in the available record. Rowland's words to Jenkins are documented in Monsanto's own contemporaneous email; his words and conduct inside the agency are not.

Dan Jenkins — Monsanto Regulatory Affairs Manager. The Monsanto Papers establish that Jenkins was Monsanto's point of contact with Jess Rowland and authored the April 2015 internal email recounting Rowland's "if I can kill this I should get a medal" statement. What the evidence establishes: Jenkins managed Monsanto's regulatory affairs and cultivated a relationship with the chair of the EPA committee reviewing glyphosate. What has been alleged: plaintiffs and critics have characterized Jenkins as the company's channel for improper regulatory influence. What the evidence does not establish: the full scope and frequency of Jenkins' communications with Rowland, whether Jenkins initiated or responded to Rowland's offer, and whether Jenkins acted on his own initiative or at the direction of more senior Monsanto officers. Jenkins' email is a contemporaneous business record, and it documents the communication; it does not document the full relationship.

Dr. William F. Heydens — Monsanto Toxicologist. The Monsanto Papers establish that Heydens drafted substantial portions of the 2000 Williams-Kroes-Munro safety review and discussed in internal emails the strategy of recruiting academic scientists as "external authors" to lend independent credibility to company-prepared text. What the evidence establishes: Heydens was the operational lead on a ghostwriting project that produced a publication deployed in regulatory submissions for over a decade. What has been alleged: plaintiffs, journalists, and academic critics have characterized Heydens as the architect of a deliberate strategy to contaminate the scientific literature with corporate-authored publications disguised as independent science. What the evidence does not establish: whether Heydens ghostwrote or directed ghostwriting of other publications beyond the 2000 study; whether Heydens believed that glyphosate posed a carcinogenic risk — his internal communications treat the product as safe, and the available documents do not distinguish between genuine belief and strategic positioning. Heydens' ghostwriting role is established; whether it was an isolated incident or part of a broader practice is not.

Source Weighting

Tier 1 — Primary institutional findings within domain:

IARC Monograph 112 (WHO agency producing formal hazard classification through documented process)
EPA regulatory determinations (federal agency within its statutory authority, though independence is contested — see Reweighting below)
Jury verdicts in Johnson, Hardeman, Pilliod (legal findings by duly-constituted juries; civil standard)
The reported 2025 journal retraction (formal editorial action by an academic journal within its domain; date per case submission, pending verification)

Tier 2 — Primary-source documents disclosed in litigation:

The Monsanto Papers (internal company documents; contemporaneous records of Monsanto's internal conduct; the weight of the evidence does not depend on any external interpretation — the documents speak for themselves on what Monsanto employees were doing internally)

Tier 3 — Contested interpretations of scientific evidence:

Competing meta-analyses and reviews of the epidemiological literature on glyphosate and NHL
Expert testimony on both sides of the litigation

Reweighting under the candidate-as-evidence-producer principle: The EPA's glyphosate assessment relied in substantial part on unpublished industry studies submitted by Monsanto and on a published literature that included the ghostwritten 2000 study. Monsanto was both the regulated entity and the primary producer of the safety evidence on which the EPA's assessment rested. The EPA itself is an independent agency, but the evidence stream it relied on was shaped by the candidate institution. The structural vulnerability is not unique to glyphosate: under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), the EPA does not conduct its own independent toxicity studies for pesticide registration — it reviews studies submitted by the registrant. The system is structurally dependent on industry-supplied data. In this case, that structural dependence was compounded by the documented relationship between the company and the chair of the EPA's Cancer Assessment Review Committee. Under the methodology's reweighting principle, the EPA's finding cannot be treated as a neutral institutional determination wholly independent of Monsanto's influence. The weight that attaches to the EPA finding is reduced — not to zero, but to a level that reflects the structural dependence on company-produced evidence, the contamination of the published literature the EPA reviewed, and the documented relationship between the company and a key EPA official. Independent corroboration from outside Monsanto's reach — which IARC's process provided by relying on publicly available studies and operating without industry participation in the working group — becomes the load-bearing standard.

Anomalies

HIGH significance:

The ghostwritten 2000 safety review. Monsanto toxicologist Dr. William F. Heydens and colleagues drafted what became the Williams-Kroes-Munro safety review, published under the names of three academic scientists without disclosure of Monsanto's authorship. Heydens' internal emails explicitly discuss the strategy: recruiting academic "external authors" to lend independent credibility to company-prepared text. The study was cited in regulatory submissions and the scientific literature as if it were independent peer-reviewed science for more than a decade. This is a direct assault on the integrity of the scientific literature — not a marginal dispute over methodology. The reported retraction in 2025 formally closes the institutional loop. Significance is HIGH: the study was load-bearing for regulatory safety findings, and its purported independence was fraudulent.
The Jess Rowland communications — EPA CARC chair as company ally. Jess Rowland chaired the EPA's Cancer Assessment Review Committee — the body responsible for the EPA's glyphosate cancer assessment. In April 2015, Monsanto regulatory affairs manager Dan Jenkins recounted in an internal email that Rowland had told him, regarding a planned ATSDR glyphosate review, "if I can kill this I should get a medal." Internal Monsanto documents express confidence that Rowland would manage the EPA's own assessment favorably. The documented offer by the regulator chairing the relevant review committee to suppress an interagency review is, in any investigation of regulatory capture, itself cause for formal inquiry. Significance is HIGH.
The IARC-EPA divergence — opposite conclusions from the same evidence base. The IARC and the EPA examined essentially the same chemical and reached opposite public-health conclusions: "probably carcinogenic" (IARC) versus "not likely carcinogenic" (EPA). The EPA's conclusion was reached by a Cancer Assessment Review Committee chaired by Jess Rowland — the same official who, in the company's own contemporaneous words, was operating as an ally of Monsanto. IARC's process excluded industry-affiliated scientists from its working group and relied on publicly available studies; the EPA's process included unpublished industry data and was structurally dependent on the registrant's submissions under FIFRA. The divergence is not proof of corruption — reasonable agencies applying different frameworks (hazard vs. risk) can differ — but the divergence occurred through a process that the Monsanto Papers show was the target of active corporate cultivation at its highest level. Significance is HIGH.

MODERATE significance:

The retraction delay and what is not known about the journal's internal process. The ghostwriting was publicly exposed in 2017 with the first wave of Monsanto Papers disclosures. The retraction by Regulatory Toxicology and Pharmacology (an Elsevier journal) occurred in November 2025 — eight years later. During that period, the compromised study continued to sit in the scientific literature, available for citation and capable of influencing reviews, meta-analyses, and regulatory assessments. The delay raises questions about the institutional safeguards at the journal and its publisher. However, the available record does not establish when the journal was formally notified of the ghostwriting with supporting evidence, what internal review process it undertook, or whether any party formally requested retraction prior to 2025. Public disclosure in litigation is not equivalent to formal notification to a journal editor. The eight-year gap between public exposure and institutional acknowledgment is a significant fact; the Brief cannot, on the available record, attribute it confidently to institutional tolerance rather than process delay, and the two possibilities are not mutually exclusive. Significance is MODERATE, and the gap in the record about the journal's internal timeline is itself noted.
The pattern of jury findings across two court systems. Three separate juries — one in San Francisco Superior Court (Johnson, 2018), one in federal MDL (Hardeman, 2019), and one in Alameda County Superior Court (Pilliod, 2019) — evaluating different plaintiffs with different exposure histories, all found that Roundup caused the plaintiffs' cancer and that Monsanto failed to warn. The consistency across two different court systems and three different juries, each hearing extensive evidence including the Monsanto Papers, is notable. Counterweight: all three damage awards were substantially reduced on appeal, and each judge (Bolanos, Chhabria, Smith) expressed concerns about the quantum of damages, suggesting judicial unease with at least the jury's damages calculus.
The acquisition-verdict timing. Bayer closed its $63 billion acquisition of Monsanto in June 2018. The Johnson verdict — a $289 million finding that Roundup caused cancer and Monsanto failed to warn — was delivered in August 2018, two months later. Bayer's management acquired a litigation time bomb they apparently did not fully price into the transaction. The subsequent commitment of over $10 billion to settle claims, coming from Bayer rather than legacy Monsanto, means the financial consequences of conduct that occurred under Monsanto's watch were borne by a different company's shareholders. Significance is MODERATE as a narrative fact; it does not bear on the scientific or regulatory questions directly, but it shapes the commercial context in which the settlements must be understood.
Uncertainty about the extent of ghostwriting beyond the single documented study. The Monsanto Papers documented one instance of ghostwriting — the 2000 study. Heydens' emails discussing the strategy of recruiting academic authors suggest a methodology, not an isolated incident, but only one publication has been documented and retracted. Whether other studies in the glyphosate safety literature were similarly compromised is not established. The uncertainty itself is an anomaly: the scientific literature on which regulatory safety findings rest may contain additional undisclosed corporate-authored publications. Significance is MODERATE.

LOW significance:

Monsanto's pre-publication strategy against IARC. Companies defend their products, and preparing a response to an anticipated adverse regulatory finding is not in itself anomalous. The anomaly, if any, is in the specific tactics — planning to "orchestrate" outcry and using third-party scientists without disclosure — but these tactics are better addressed under the ghostwriting anomaly than as a separate item. Significance is LOW.

Motive and Mechanism

Motive: Monsanto's motive to protect glyphosate's safety profile was direct, powerful, and fully documented. Roundup was a flagship product generating billions in annual revenue. More significantly, Roundup's safety was the premise on which the company's genetically-modified seed business was built: "Roundup Ready" crops assume a herbicide safe enough to use liberally. A finding that glyphosate is carcinogenic would threaten not only the herbicide business but the entire GMO product architecture. The company had both financial motive and strategic motive — and the IARC finding, if accepted by regulators, would trigger review, labeling requirements, and potential bans across jurisdictions.

Mechanism: The Monsanto Papers document a multi-pronged mechanism for shaping the scientific and regulatory environment:

Literature seeding: Ghostwriting or commissioning safety reviews, publishing them under academic names, and then citing those publications in regulatory submissions as independent science. The 2000 Williams-Kroes-Munro study is the documented instance; Heydens' internal communications discussing the recruitment of academic "external authors" suggest this was a deliberate strategy rather than an isolated act.
Regulator cultivation: Building relationships with key regulatory officials — Jess Rowland, chair of the EPA's Cancer Assessment Review Committee, is the documented instance — who could influence assessments, block interagency reviews, and provide inside information. The mechanism was not crude bribery (no evidence of payments to Rowland has emerged) but a cultivated alignment of interests and personal rapport that produced favorable regulatory treatment.
Adverse-finding neutralization: Planning and executing coordinated responses to unfavorable findings — in the IARC case, before the finding was even public — including recruiting third-party scientists to publish rebuttals without disclosing Monsanto's role, engaging PR firms, and lobbying regulatory agencies to reject the finding. The mechanism was to create a counter-narrative enabling regulators to dismiss IARC as flawed science.
Litigation defense: Once litigation commenced, Monsanto and later Bayer defended glyphosate's safety aggressively in court, relying on the body of scientific literature — including the ghostwritten study — that the company had helped create. The mechanism came full circle: science the company shaped was deployed to defend the company in proceedings where that science was at issue.

Separating motive from mechanism: The motive (protecting a multi-billion-dollar product line) is established beyond reasonable dispute. The mechanism (ghostwriting, regulator cultivation, coordinated response) is documented in the Monsanto Papers. What remains unproven is the final link: whether the mechanism actually caused the EPA and other agencies to reach conclusions they would not have reached in its absence. The EPA's position that glyphosate is safe predated the documented Rowland communications, and multiple regulatory bodies without documented Monsanto influence (EFSA, for instance) reached similar conclusions. The mechanism is documented; its regulatory effect is inferred.

Competing Theories

Theory	Proponent / Source	Evidentiary Basis	Confidence
Glyphosate is carcinogenic and Monsanto concealed the risk	Plaintiffs' bar, IARC-associated scientists, environmental groups	IARC Monograph 112; epidemiological studies showing associations; Monsanto Papers showing ghostwriting and regulatory influence; jury verdicts in two court systems	MODERATE — the concealment of corporate influence on the literature is established; whether glyphosate actually causes NHL at exposure levels remains disputed among qualified scientists
Glyphosate is safe; Monsanto's conduct was aggressive but did not affect the underlying science; IARC was wrong	Bayer/Monsanto, EPA, EFSA, some academic scientists	Multiple regulatory assessments finding glyphosate not carcinogenic; Agricultural Health Study not showing clear association; IARC's process criticized for excluding certain industry data	MODERATE — the regulatory consensus outside IARC is real; the ghostwriting and Rowland communications, however, make it impossible to treat the regulatory consensus as fully independent
Glyphosate is safe, but Monsanto's ghostwriting was separately improper and created unwarranted public alarm	Intermediate position held by some commentators	Accepts the regulatory science on safety but condemns the ghostwriting as misconduct	LOW to MODERATE — logically coherent but has few institutional proponents
The IARC finding and litigation were a coordinated attack on Monsanto by the organic food industry and anti-GMO activists	Monsanto's initial public response; circulating in industry-aligned discourse	The organic industry did benefit from undermining glyphosate's reputation	VERY LOW — no primary-source evidence of coordination; the IARC working group was composed of independent scientists; the Monsanto Papers are internal documents, not activist fabrications

THE STRONG CIRCUMSTANTIAL READING: CORPORATE MANIPULATION OF SCIENCE AND REGULATION TO PROTECT A FLAGSHIP PRODUCT

The reading that the Monsanto Papers elevate is that Monsanto Corporation — now Bayer — conducted a deliberate, multi-year campaign to manipulate the scientific literature and the regulatory process on glyphosate's safety, and that this manipulation was designed to prevent adverse findings from threatening a multi-billion-dollar product line. The reading does not require proving that glyphosate causes cancer. It requires establishing that Monsanto acted as if the safety question was too commercially important to be left to independent science.

Indicator 1 — The ghostwritten safety review, authored by a named Monsanto toxicologist. The 2000 Williams-Kroes-Munro study was not a marginal piece of the glyphosate safety literature. It was a comprehensive safety review published in a peer-reviewed journal, bearing the names of three respected academic scientists (Williams of New York Medical College, Kroes of Utrecht University, Munro of Cantox), and it concluded that glyphosate posed no carcinogenic risk to humans. The Monsanto Papers show that Monsanto toxicologist Dr. William F. Heydens drafted the manuscript, that Heydens discussed the strategy of recruiting academic "external authors" to lend independent credibility to company text, and that the company then deployed the study as independent science for more than a decade. This is not a dispute about interpretation or methodology. It is a falsification of authorship, and it contaminated the scientific record on which regulatory decisions are made. The reported 2025 retraction formally closes the episode — eight years after the ghostwriting was first exposed — but the study influenced the regulatory environment for a quarter-century.

Indicator 2 — Cultivation of the EPA official chairing the cancer review. The Jess Rowland communications are the closest the Monsanto Papers come to a smoking gun on regulatory influence. Rowland chaired the EPA's Cancer Assessment Review Committee — the body responsible for the EPA's glyphosate cancer determination. In April 2015, Monsanto regulatory affairs manager Dan Jenkins recounted in an internal email that Rowland had said regarding a planned ATSDR review: "if I can kill this I should get a medal." Internal Monsanto emails treat Rowland as an ally inside the agency who will manage the EPA's own assessment to Monsanto's benefit. These are not allegations by critics. They are Monsanto's own contemporaneous words about its relationship with the regulator chairing the relevant review committee.

Indicator 3 — Coordinated discrediting of IARC before publication. Before the IARC monograph was published, Monsanto was planning a coordinated response — engaging PR firms, recruiting third-party scientists to publish rebuttals without disclosing Monsanto's role, and lobbying regulatory agencies to reject the finding. These are internal Monsanto documents, not external allegations. They show a company that treated an adverse scientific finding as a public-relations problem to be managed rather than a scientific question to be engaged.

Indicator 4 — Adjacent operational history: the PCB and Agent Orange precedent. The methodology requires that an organized power have a track record of analogous conduct in comparable circumstances. Direct precedent for the specific mechanism at issue — ghostwriting academic safety literature — is not independently established in Monsanto's prior conduct. However, the methodology directs attention to adjacent operational history: conduct in different domains that reveals the same institutional reflexes at work. Monsanto's history on this wider view is substantial and documented in litigation and regulatory proceedings spanning decades. The company manufactured PCBs from the 1930s until 1977. Internal documents — disclosed in litigation that ultimately produced a $700 million settlement with the State of Washington, among other judgments — showed that Monsanto knew of PCB toxicity from at least the 1950s and pursued a deliberate strategy of concealing that knowledge, publicly denying the risks, and resisting regulation. The company was a primary manufacturer of Agent Orange for the US military during the Vietnam War and for years denied that dioxin contamination posed health risks, despite internal awareness. Neither case involved ghostwriting. Both cases involved the same institutional operational signature: a corporation in possession of internal evidence of toxicity, deploying legal, scientific, and public-relations resources to prevent that evidence from producing regulatory or liability consequences, over decades. This is adjacent history under the methodology: same actor, same operational reflexes, different specific mechanisms, different decades. The pattern does not prove that Monsanto ghostwrote the 2000 study because it knew glyphosate was carcinogenic. It establishes that Monsanto was an institution with an operational culture in which concealing toxicity evidence and managing regulatory environments to protect products was not aberrant — it was, across multiple products and multiple decades, how the company operated. The glyphosate case fits that institutional pattern.

Indicator 5 — Structural vulnerability of the EPA process. The EPA's pesticide-assessment process under FIFRA does not involve independent agency toxicology studies. The agency reviews studies submitted by the registrant — here, Monsanto. This structural dependence on industry data is not unique to glyphosate, but in this case it aligned with documented corporate manipulation of the evidence stream: the company that submitted the data was also ghostwriting the published literature and cultivating the regulator chairing the review committee. The regulatory system was structurally vulnerable to precisely the kind of manipulation the Monsanto Papers document.

Indicator 6 — Pattern consistency across multiple fronts and years. The ghostwriting (led by Heydens), the Rowland relationship (recounted by Jenkins), and the IARC response are not isolated incidents. They form a pattern executed across multiple years by multiple named Monsanto employees: shape the literature to support safety; cultivate regulators to protect the product; neutralize adverse findings before they gain traction. The pattern is consistent with a corporate strategy of managing the scientific and regulatory environment rather than participating in it on equal terms.

Indicator 7 — Jury findings and the settlement. Three juries in two different court systems, after hearing extensive evidence including the Monsanto Papers, found that Roundup caused the plaintiffs' cancer and that Monsanto failed to warn. Bayer's decision to commit over $10 billion to settle roughly 125,000 claims — approximately two years after acquiring Monsanto, with the first adverse verdict arriving two months after the acquisition closed — is economically indistinguishable from an acknowledgment that the litigation risk was severe. Companies do not pay $10 billion to settle claims they believe they can consistently win.

What is missing that prevents proof: No document in the Monsanto Papers records a Monsanto executive stating "glyphosate causes cancer and we are hiding it." The company's internal communications treat glyphosate as safe and characterize critics as unscientific activists — a view that could reflect genuine belief, deliberate self-deception, or calculated strategy, and the available documents do not allow a definitive distinction. The epidemiological question — whether glyphosate at real-world exposure levels causes NHL — remains genuinely contested, with the large Agricultural Health Study finding no significant association while several case-control studies and meta-analyses do. The EPA's conclusion that glyphosate is safe has been maintained across administrations and officials beyond Rowland, suggesting that Rowland's influence, while documented and troubling, may not have been determinative of the agency's ultimate position. Whether the ghostwriting strategy was applied to other publications beyond the single documented study is not established.

This reading cannot be proven from available public evidence. It also cannot be dismissed. The Monsanto Papers document conduct that, even on the most generous interpretation — that Monsanto believed sincerely in its product's safety and acted aggressively to defend it — constitutes a sustained effort to distort the scientific literature and cultivate improper regulatory influence. On a less generous interpretation, the conduct amounts to a coordinated campaign to prevent the truth about glyphosate's carcinogenicity from emerging through independent science. The available evidence does not let an honest investigator choose definitively between those interpretations. What it does not permit is treating Monsanto's conduct as normal corporate advocacy.

Interpretive Choices

The Brief makes the following interpretive choices, acknowledging that alternatives are compatible with the evidence at lower weight:

The Brief treats the ghostwriting as an established fact, not a contested allegation. The Monsanto Papers provide primary-source evidence of Heydens drafting the manuscript and recruiting academic authors. The reported retraction in 2025 ratifies this reading. The alternative — that the academic authors substantively wrote the study and Monsanto's role was minor — is incompatible with the weight of the documented evidence, including Heydens' own emails.
The Brief treats the Rowland communications as evidence of improper regulatory influence, not merely aggressive lobbying. The alternative — that Rowland's "if I can kill this I should get a medal" was bluster, that his influence on the EPA's assessment was negligible, and that the EPA's conclusions were reached independently — is possible but requires discounting Monsanto's own contemporaneous confidence in Rowland's ability to deliver, expressed in internal documents.
The Brief does not take a position on the epidemiological question. It treats the causation question as genuinely unresolved among qualified scientists. The alternative — that the IARC classification or the jury verdicts settle the scientific question — overstates the evidence.
The Brief treats the settlement as economically significant but not as an admission of causation. Bayer's characterization of the settlement is self-serving, but the settlement's legal structure does not constitute an admission. The alternative — treating the settlement as proof of causation — conflates litigation economics with scientific determination.
The Brief acknowledges the gap in direct history for the ghostwriting mechanism and argues the adjacent-history case through PCB and Agent Orange precedent. The alternative — that adjacent history is too weak to support the elevated reading and the case should be routed to a standard strong circumstantial reading — is a reasonable interpretive choice. The Brief adopts the elevated reading on the strength of the supplementary indicators (operational signature, suppression pattern, structural beneficiary) in combination with the adjacent operational history, on the view that an institution with Monsanto's documented pattern of concealing toxicity evidence across multiple products and decades is precisely the kind of actor for whom the elevated reading is designed.
The Brief treats the retraction delay as an anomaly but does not attribute it confidently to institutional tolerance rather than process delay. The alternative — that the eight-year gap demonstrates systemic failure in academic publishing — is plausible but the record does not establish the journal's internal timeline. The Brief flags the gap in the record rather than filling it with inference.

SECTION 4 — WHAT REMAINS UNKNOWN

Whether glyphosate, at real-world human exposure levels, causes non-Hodgkin lymphoma. This is the central scientific question, and it remains unresolved. The IARC classification identifies a hazard; the EPA and EFSA assessments conclude the risk is not established. The epidemiological evidence is mixed: the Agricultural Health Study, a large prospective cohort of licensed pesticide applicators, has not found a statistically significant association between glyphosate exposure and NHL, though critics note limitations in follow-up duration relative to NHL latency periods. Several case-control studies and meta-analyses do report positive associations. The question may never be resolved definitively, because a randomized controlled trial exposing humans to glyphosate to test carcinogenicity is neither ethical nor feasible, and observational studies carry inherent limitations in exposure measurement and confounding control.

What Jess Rowland actually did inside the EPA. The Monsanto Papers document what Rowland told Monsanto he could do and what Monsanto believed he was doing. They do not document Rowland's actual conduct within the agency — the specific actions he took, the internal discussions he participated in, the influence he exerted on the EPA's Cancer Assessment Review Committee's deliberations. The EPA's internal deliberative processes are generally not public, and the available evidence does not fill the gap between Rowland's words to Dan Jenkins and his actions within the agency.

Whether other safety studies in the glyphosate literature were similarly ghostwritten or industry-influenced. The Monsanto Papers documented one instance of ghostwriting — the 2000 Williams-Kroes-Munro study — led by Dr. William Heydens. Heydens' emails discussing the strategy of recruiting academic "external authors" suggest a methodology, not an isolated incident, but only one publication has been documented and retracted. The full extent of ghostwriting in the glyphosate safety literature is not known, and the scientific literature on which regulatory safety findings rest may contain additional undisclosed corporate-authored publications.

The full scope of Monsanto's regulatory influence efforts beyond the EPA. The Monsanto Papers were disclosed in US civil litigation. They represent documents that survived discovery and were not protected by privilege claims. Whether Monsanto engaged in similar conduct with other regulatory agencies — EFSA, national regulators in other jurisdictions — is not documented in the available record. The absence of evidence from other jurisdictions does not establish absence of conduct.

Whether the ghostwritten study altered specific regulatory outcomes. The 2000 study was cited in regulatory submissions for years. But regulatory bodies like EFSA reached their conclusions through independent review processes with access to evidence beyond the published literature. Establishing a causal link between the ghostwritten study and any specific regulatory determination remains difficult and may be unanswerable given the number of variables in any regulatory decision.

The journal's internal timeline for the retraction. Regulatory Toxicology and Pharmacology retracted the 2000 study eight years after the ghostwriting was publicly exposed in litigation. The available record does not establish when the journal was formally notified of the ghostwriting with supporting evidence, what internal review process it undertook, whether any party formally requested retraction before 2025, or whether the delay reflects institutional tolerance or ordinary — if extended — editorial process. The gap in the record is itself noted.

Whether Monsanto had previously ghostwritten other safety studies beyond the 2000 publication. The adjacent operational history — PCB concealment, Agent Orange denial — establishes a corporate pattern of concealing toxicity evidence across products and decades. It does not establish a specific precedent for academic ghostwriting. Whether the ghostwriting strategy in the glyphosate case was novel or a refinement of a pre-existing practice is not known.

SECTION 5 — METHODOLOGICAL NOTE

This case is methodologically distinctive for three features. First, the unusual convergence of four evidentiary streams that rarely align in a single corporate-conduct investigation: internal corporate documents (the Monsanto Papers), a formal regulatory divergence between two credible institutional bodies (IARC and EPA), civil litigation outcomes in two different court systems, and an academic-institutional action (the reported 2025 retraction). Second, the structural challenge of a case where the documented corporate misconduct — ghostwriting, regulator cultivation, coordinated discrediting of adverse science — is established, but the underlying scientific question (whether glyphosate causes cancer) remains genuinely unresolved, requiring the Brief to hold both the corporate-conduct reading and the scientific uncertainty in view simultaneously. Third, the history pillar of the organized-power triad presented a specific analytical difficulty: direct precedent for academic ghostwriting was not independently established, requiring the Brief to argue the adjacent-history case through Monsanto's documented PCB and Agent Orange conduct — same institutional operational signature, different specific mechanisms, different decades — and to lean on the supplementary indicators to support elevation. This is the methodology's adjacent-history pathway operating as designed, and the Brief explicitly surfaces the interpretive choice rather than treating the history as more firmly established than it is.